Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In 2001, we proposed to restore this balance using judicious doses of antiangiogenic agents and suggested that this strategy would transiently give rise to tumour vessels with structural and functional phenotypes closer to those of the vessels of nonmalignant tissues — a state we referred to as ‘normalized’ (REF. 61)”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [61]
In the citing paper
“We also suggested that the use of other therapies during this ‘window of normalization’ (REF. 61) would result in better outcomes than if the same agents were given before or after this window.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [61]
In the citing paper
“Traditional angiogenesis inhibitors mainly block VEGF signaling and prune rather than eradicate tumor vessels.”
From Hypoxia signaling in cancer: Implications for therapeutic interventions (2023) · cites this paper as [78]
Citations
Cites
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070 · cited 1×
“What mechanisms are responsible for this normalization? How can we exploit them? This knowledge will affect the treatment not only of cancer but also of other diseases characterized by abnormal vasculature—such as hemangiomas, arteriovenous malformations, diabetic retinopathy and macular degeneration—for which anti-an…”
BackgroundSelf-citationGenes Expressed in Human Tumor Endothelium
Croix, B. S., Rago, C., Velculescu, V., Traverso, G., Romans, K. E., Montgomery, E., Lal, A., Riggins, G. J., Lengauer, C., Vogelstein, B., et al. (2000) · Science · doi:10.1126/science.289.5482.1197 · Cited by 1,845
Browder, T. D., Butterfield, C., Kräling, B. M., Shi, B., Marshall, B., OʼReilly, M., & Folkman, J. (2000) · PubMed · Cited by 1,720
Benjamin, L. E., Golijanin, D., Itin, A., Pode, D., & Keshet, E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5028 · Cited by 1,241
Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., & Kerbel, R. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8829 · Cited by 1,168
Barriers to Drug Delivery in Solid Tumors
Jain, R. K. (1994) · Scientific American · doi:10.1038/scientificamerican0794-58 · Cited by 1,069
Self-citationLee, C. G., Heijn, M., di Tomaso, E., Griffon, G., Ancukiewicz, M., Koike, C., Park, K. R., Ferrara, N., Jain, R. K., Suit, H. D., et al. (2000) · PubMed · Cited by 733
Self-citationYuan, F., Chen, Y., Dellian, M., Safabakhsh, N., Ferrara, N., & Jain, R. K. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.25.14765 · Cited by 719
Self-citationBaish, J. W., & Jain, R. K. (2000) · PubMed · Cited by 714
Self-citationThe next frontier of molecular medicine: Delivery of therapeutics
Jain, R. K. (1998) · Nature Medicine · doi:10.1038/nm0698-655 · Cited by 407
Self-citation
Research works printed but not linked: 6
- Folkman, J. in Harrison's Textbook of Internal Medicine, 15th ed. (eds Braunwald, E. et al.) 517–530 (McGraw-Hill, New York, 2001).
- Kozin, S.V. et al. VEGF receptor-2 blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res. 61, 39–44 (2001).
- Tsuzuki, Y. et al. VEGF modulation by targeting HIF-1α→HRE→VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Research 60, 6248–6252 (2000).
- Kadambi, A. et al. Vascular endothelial growth factor (VEGF)–C differentially affects tumor vascular function and leukocyte recruitment. Cancer Res. 61, 2404–2408 (2001).
- Lee, C.G. et al. Anti-VEGF treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 60, 5565–5570 (2000).
- Hansen-Algenstaedt, N. et al. Tumor oxygenation during VEGFR-2 blockade, hormone ablation, and chemotherapy. Cancer Res. 60, 4556–4560 (2000).
Cited by
Items 201–300 of 1,004
Patel, J. D., Hensing, T. A., Rademaker, A., Hart, E. M., Blum, M. G., Milton, D. T., & Bonomi, P. D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.8181 · Cited by 178
Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity
Martin, J. D., Fukumura, D., Duda, D. G., Boucher, Y., & Jain, R. K. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a027094 · Cited by 175
Self-citationTumor response assessments with diffusion and perfusion MRI
Li, S. P., & Padhani, A. R. (2012) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.22838 · Cited by 180
“‘‘Normalization’’ of the vasculature by antiangiogenic drugs as described originally by Jain (114) can be detected on DCE-MRI by regional increases in nonenhancing pixels (representing vascular pruning) with reductions in permeability and leakage space.”
BackgroundHua, Y., Vella, G., Rambow, F., Allen, E., Antoranz Martinez, A., Duhamel, M., Takeda, A., Jalkanen, S., Junius, S., Smeets, A., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.11.002 · Cited by 169
Sonveaux, P., Brouet, A., Havaux, X., Grégoire, V., Dessy, C., Balligand, J., & Féron, O. (2003) · PubMed · Cited by 180
Herbst, R. S., Mullani, N. A., Davis, D. W., Hess, K. R., McConkey, D. J., Charnsangavej, C., O’Reilly, M. S., Kim, H.-W., Baker, C., Roach, J., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.05.102 · Cited by 180
Lu-Emerson, C., Duda, D. G., Emblem, K. E., Taylor, J. W., Gerstner, E. R., Loeffler, J. S., Batchelor, T. T., & Jain, R. K. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.9575 · Cited by 179
“angiogenic agents—normalization of abnormal tumor vessels—to increase tumor blood perfusion and decrease hypoxia.(29) Indeed, several preclinical studies support this notion.”
BackgroundSelf-citationRole of vascular normalization in benefit from metronomic chemotherapy
Mpekris, F., Baish, J. W., Stylianopoulos, T., & Jain, R. K. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700340114 · Cited by 178
“Vessel normalization repairs the structure and function of the tumor vessel wall and tumor vascular network, and can improve tumor perfusion and oxygenation (12, 15).”
BackgroundSelf-citationWhat brings pericytes to tumor vessels?
Jain, R. K., & Booth, M. F. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200320087 · Cited by 175
Self-citationBevacizumab: A Review of Its Use in Advanced Cancer
Keating, G. M. (2014) · Drugs · doi:10.1007/s40265-014-0302-9 · Cited by 177
Photonanomedicine: a convergence of photodynamic therapy and nanotechnology
Obaid, G., Broekgaarden, M., Bulin, A.-L., Huang, H.-C., Kuriakose, J., Liu, J., & Hasan, T. (2016) · Nanoscale · doi:10.1039/c5nr08691d · Cited by 168
Pillé, J.-Y., Li, H., Blot, E., Bertrand, J.-R., Pritchard, L.-L., Opolon, P., Maksimenko, A., Lu, H., Vannier, J.-P., Soria, J., et al. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.1019 · Cited by 167
Modulation of the tumor vasculature and oxygenation to improve therapy
Siemann, D. W., & Horsman, M. R. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.06.006 · Cited by 169
“It has been suggested that targeting angiogenesis could reduce or abolish vascular abnormalities leading to vessel stabilization or normalization, resulting in a more efficient vasculature similar to that seen in normal tissues (Jain, 2001).”
Imaging angiogenesis and the microenvironment
FUKUMURA, D., & JAIN, R. K. (2008) · APMIS · doi:10.1111/j.1600-0463.2008.01148.x · Cited by 162
Self-citationLessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer
Jain, R. K. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2346 · Cited by 165
Self-citationA review of mathematical models for the formation of vascular networks
Scianna, M., Bell, C. G., & Preziosi, L. (2013) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2013.04.037 · Cited by 167
“In fact, counterintuitively, Jain and co-workers [109, 130, 131] have hypothesized that it is important to normalise the vascular network through the restoration of a proper balance of pro-angiogenic and anti-angiogenic factors in order to achieve a better delivery of drugs.”
BackgroundMethodResultInfluentialCascone, T., Herynk, M. H., Xu, L., Du, Z., Kadara, H., Nilsson, M. B., Oborn, C. J., Park, Y.-Y., Erez, B., Jacoby, J. J., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci42405 · Cited by 164
Endothelial cells in tumor microenvironment: insights and perspectives
Leone, P., Malerba, E., Susca, N., Favoino, E., Perosa, F., Brunori, G., Prete, M., & Racanelli, V. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1367875 · Cited by 167
Thalidomide Radiosensitizes Tumors through Early Changes in the Tumor Microenvironment
Ansiaux, R., Baudelet, C., Jordan, B. F., Beghein, N., Sonveaux, P., De Wever, J., Martinive, P., Grégoire, V., Feron, O., & Gallez, B. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.743.11.2 · Cited by 163
Milosevic, M., Fyles, A., Hedley, D., & Hill, R. (2004) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2004.04.006 · Cited by 163
Lysophospholipid Mediators in Health and Disease
Kano, K., Aoki, J., & Hla, T. (2021) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-050420-025929 · Cited by 172
Wang, D., Xu, Z., Yu, H., Chen, X., Feng, B., Cui, Z., Lin, B., Yin, Q., Zhang, Z., Chen, C., et al. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.05.094 · Cited by 163
Waite, C. L., & Roth, C. M. (2012) · Critical Reviews in Biomedical Engineering · doi:10.1615/critrevbiomedeng.v40.i1.20 · Cited by 156
Schmitz, C. H., Klemer, D. P., Hardin, R., Katz, M. S., Pei, Y., Graber, H. L., Levin, M. B., Levina, R. D., Franco, N. A., Solomon, W. B., et al. (2005) · Applied Optics · doi:10.1364/ao.44.002140 · Cited by 161
Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting
Tseng, C.-L., Wang, T.-W., Dong, G.-C., Yueh-Hsiu Wu, S., Young, T.-H., Shieh, M.-J., Lou, P.-J., & Lin, F.-H. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2007.05.006 · Cited by 160
Miles, D., Harbeck, N., Escudier, B., Hurwitz, H., Saltz, L., Van Cutsem, E., Cassidy, J., Mueller, B., & Sirzén, F. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.2794 · Cited by 158
Targeting vascular and leukocyte communication in angiogenesis, inflammation and fibrosis
Kreuger, J., & Phillipson, M. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.2 · Cited by 160
Zhu, A. X., Holalkere, N. S., Muzikansky, A., Horgan, K., & Sahani, D. V. (2008) · The Oncologist · doi:10.1634/theoncologist.2007-0174 · Cited by 161
Dolmans, D. E. J. G. J., Kadambi, A., Hill, J. S., Waters, C. A., Robinson, B. C., Walker, J. P., Fukumura, D., & Jain, R. K. (2002) · PubMed · Cited by 184
Self-citationAbdollahi, A., Lipson, K. E., Sckell, A., Zieher, H., Klenke, F. M., Poerschke, D., Roth, A. K., Han, X., Krix, M., Bischof, M., et al. (2003) · PubMed · Cited by 178
Modulating inflammation for cancer therapy
Ritter, B., & Greten, F. R. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20181739 · Cited by 159
“However, the efficacy of antiangiogenic therapies continues to be limited, and the mechanism of action (vascular regression vs. vascular normalization) is poorly understood (Klement et al., 2000; Jain, 2001).”
BackgroundKaul, G., & Amiji, M. M. (2004) · Journal of drug targeting · doi:10.1080/10611860400013451 · Cited by 159
Targeting the Metabolic Microenvironment of Tumors
Bailey, K. M., Wojtkowiak, J. W., Hashim, A. I., & Gillies, R. J. (2012) · Advances in Pharmacology · doi:10.1016/b978-0-12-397927-8.00004-x · Cited by 154
Perspectives for Improving the Tumor Targeting of Nanomedicine via the EPR Effect in Clinical Tumors
Kim, J., Cho, H., Lim, D., Joo, M. K., & Kim, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210082 · Cited by 180
Morphologic Instability and Cancer Invasion
Cristini, V., Frieboes, H. B., Gatenby, R., Caserta, S., Ferrari, M., & Sinek, J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0852 · Cited by 163
Overcoming key biological barriers to cancer drug delivery and efficacy
Kim, S. M., Faix, P. H., & Schnitzer, J. E. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.016 · Cited by 151
Hit 'Em Where They Live: Targeting the Cancer Stem Cell Niche
Yang, Z.-J., & Wechsler‐Reya, R. J. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.12.007 · Cited by 172
Role of Lymphangiogenesis in Cancer
Sundar, S. S., & Ganesan, T. S. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.1092 · Cited by 164
Mechanisms of Action of Bevacizumab as a Component of Therapy for Metastatic Colorectal Cancer
Ellis, L. M. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.08.002 · Cited by 172
Evidence of angiogenic vessels in Alzheimer’s disease
Desai, B. S., Schneider, J. A., Li, J.-L., Carvey, P. M., & Hendey, B. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0226-9 · Cited by 153
“Such vascular abnormalities may also contribute to impaired blood flow, reduced nutrient delivery (Jain 2001), and entry of otherwise restricted infiltrates (Kalaria 1992).”
Antiangiogenic cancer treatment: The great discovery and greater complexity (Review)
Maj, E., Papiernik, D., & Wietrzyk, J. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3709 · Cited by 147
Niu, Y., Zhu, J., Li, Y., Shi, H., Gong, Y., Li, R., Huo, Q., Ma, T., & Liu, Y. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.03.012 · Cited by 154
Targets for pharmacological intervention of endothelial hyperpermeability and barrier function.
Amerongen, G. P. V. N., & van Hinsbergh, V. (2002) · Vascular Pharmacology · doi:10.1016/s1537-1891(03)00014-4 · Cited by 109
Tumor Vascular Changes Mediated by Inhibition of Oncogenic Signaling
Qayum, N., Muschel, R. J., Im, J. H., Balathasan, L., Koch, C. J., Patel, S., McKenna, W. G., & Bernhard, E. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0657 · Cited by 146
Invasion as limitation to anti-angiogenic glioma therapy
Lamszus, K., Kunkel, P., & Westphal, M. (2003) · Springer eBooks · doi:10.1007/978-3-7091-6090-9_23 · Cited by 169
Monotherapy and Combination Therapy Using Anti‐Angiogenic Nanoagents to Fight Cancer
Liang, P., Ballou, B. T., Lv, X., Si, W., Bruchez, M. P., Huang, W., & Dong, X. (2021) · Advanced Materials · doi:10.1002/adma.202005155 · Cited by 161
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials
Kuo, H., Khan, K. A., & Kerbel, R. S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00886-y · Cited by 151
Marcus, C. D., Ladam-Marcus, V., Cucu, C., Bouché, O., Lucas, L., & Hoeffel, C. C. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.07.012 · Cited by 157
Recent progress of carbon dots in targeted bioimaging and cancer therapy
Shen, C., Liu, H.-R., Lou, Q., Wang, F., Liu, K.-K., Dong, L. R., & Shan, C. (2022) · Theranostics · doi:10.7150/thno.70721 · Cited by 150
The role of angiogenesis in solid tumours: An overview
Makrilia, N., Lappa, T., Xyla, V., Nikolaidis, I., & Syrigos, K. (2009) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2009.07.009 · Cited by 171
Jiang, W., Zhang, Z., Wang, Q., Dou, J., Zhao, Y., Ma, Y., Liu, H., Xu, H., & Wang, Y. (2019) · Nano Letters · doi:10.1021/acs.nanolett.9b01458 · Cited by 146
Vascular normalisation as the stepping stone into tumour microenvironment transformation
Magnussen, A. L., & Mills, I. G. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01330-z · Cited by 146
McGee, M. C., Hamner, J. B., Williams, R. F., Rosati, S. F., Sims, T. L., Ng, C. Y., Gaber, M. W., Calabrese, C., Wu, J., Nathwani, A. C., et al. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.12.010 · Cited by 137
Robust 3-D Modeling of Vasculature Imagery Using Superellipsoids
Tyrrell, J. A., di Tomaso, E., Fuja, D. G., Tong, R. T., Kozak, K. R., Jain, R. K., & Roysam, B. (2007) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2006.889722 · Cited by 152
Self-citationVEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects
Duda, D. G., Batchelor, T. T., Willett, C. G., & Jain, R. K. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.04.001 · Cited by 156
Self-citationSiu, A., Wind, J. J., Iorgulescu, J. B., Chan, T. A.-T., Yamada, Y. J., & Sherman, J. H. (2011) · Acta Neurochirurgica · doi:10.1007/s00701-011-1228-6 · Cited by 151
Allen, J. A., Adlakha, A., & Bergethon, P. R. (2006) · Archives of Neurology · doi:10.1001/archneur.63.10.1475 · Cited by 145
Developments and Challenges for mAb-Based Therapeutics
Goswami, S., Wang, W., Arakawa, T., & Ohtake, S. (2013) · Antibodies · doi:10.3390/antib2030452 · Cited by 144
“For example, bevacizumab binds to the soluble vascular endothelial growth factor (VEGF), and thus inhibits angiogenesis, which is important for the maintenance of tumor vasculature and tumor health [24].”
BackgroundMultiparameter Computational Modeling of Tumor Invasion
Bearer, E. L., Lowengrub, J. S., Frieboes, H. B., Chuang, Y.-L., Jin, F., Wise, S. M., Mauro Ferrari, B., Agus, D. B., & Vittorio Cristini, C. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3834 · Cited by 156
Wang, S.-B., Chen, Z.-X., Gao, F., Zhang, C., Zou, M.-Z., Ye, J.-J., Zeng, X., & Zhang, X.-Z. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119772 · Cited by 143
Sunar, U., Quon, H., Durduran, T., Zhang, J., Du, J., Zhou, C., Yu, G., Choe, R., Kilger, A., Lustig, R., et al. (2006) · Journal of Biomedical Optics · doi:10.1117/1.2397548 · Cited by 152
Duda, D. G., Jain, R. K., & Willett, C. G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.3985 · Cited by 138
Self-citationCurrent Treatments for Advanced Stage Non-Small Cell Lung Cancer
Stinchcombe, T. E., & Socinski, M. A. (2009) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200809-110lc · Cited by 152
Stylianopoulos, T., Soteriou, K., Fukumura, D., & Jain, R. K. (2013) · Annals of Biomedical Engineering · doi:10.1007/s10439-012-0630-4 · Cited by 139
Self-citationEvolving Treatment of Advanced Colon Cancer
Segal, N. H., & Saltz, L. B. (2009) · Annual Review of Medicine · doi:10.1146/annurev.med.60.041807.132435 · Cited by 140
Pillé, J.-Y., Li, H., Blot, E., Bertrand, J.-R., Pritchard, L.-L., Opolon, P., Maksimenko, A., Lu, H., Vannier, J.-P., Soria, J., et al. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.ft-248 · Cited by 140
The Warburg Effect in Endothelial Cells and its Potential as an Anti-angiogenic Target in Cancer
Fitzgerald, G., Soro-Arnáiz, I., & Bock, K. D. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00100 · Cited by 145
Metastatic Renal Carcinoma: Evaluation of Antiangiogenic Therapy with Dynamic Contrast-enhanced CT
Fournier, L. S., Oudard, S. M., Thiam, R., Trinquart, L., Banu, E., Médioni, J., Balvay, D., Châtellier, G., Frija, G. G., & Cuénod, C. A. (2010) · Radiology · doi:10.1148/radiol.10091362 · Cited by 139
Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma
Brem, S., Grossman, S. A., Carson, K. A., New, P., Phuphanich, S., Alavi, J. B., Mikkelsen, T., & Fisher, J. D. (2005) · Neuro-Oncology · doi:10.1215/s1152851704000869 · Cited by 132
Kratz, F., & Warnecke, A. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.05.045 · Cited by 136
Lee, S. M., Woll, P. J., Rudd, R., Ferry, D. R., O'Brien, M. E. R., Middleton, G., Spiro, S. G., James, L. E., Ali, K., Jitlal, M., et al. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp200 · Cited by 136
Galectins as Molecular Targets for Therapeutic Intervention
Dings, R. P. M., Miller, M. C., Griffin, R. J., & Mayo, K. H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030905 · Cited by 158
Limitations of Anti-Angiogenic Treatment of Tumors
Ribatti, D., Annese, T., Ruggieri, S., Tamma, R., & Crivellato, E. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.04.022 · Cited by 142
Hypoxic tumor microenvironment: Implications for cancer therapy
Roy, S., Kumaravel, S., Sharma, A., Duran, C. L., Bayless, K. J., & Chakraborty, S. (2020) · Experimental Biology and Medicine · doi:10.1177/1535370220934038 · Cited by 141
Wang-Bishop, L., Kimmel, B. R., Ngwa, V. M., Madden, M. Z., Baljon, J. J., Florian, D. C., Hanna, A., Pastora, L. E., Sheehy, T. L., Kwiatkowski, A. J., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.add1153 · Cited by 126
Liu, X., Ide, J. L., Norton, I. H., Marchionni, M. A., Ebling, M. C., Wang, L. Y., Davis, E., Sauvageot, C., Kesari, S., Kellersberger, K. A., et al. (2013) · Scientific Reports · doi:10.1038/srep02859 · Cited by 134
Immune Checkpoint Inhibitors in the Treatment of HCC
Donisi, C., Puzzoni, M., Ziranu, P., Lai, E., Mariani, S., Saba, G., Impera, V., Dubois, M., Persano, M., Migliari, M., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.601240 · Cited by 147
Ernsting, M. J., Hoang, B., Lohse, I., Undzys, E., Cao, P., Do, T., Gill, B., Pintilie, M., Hedley, D., & Li, S.-D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.03.023 · Cited by 133
Impact of Angiogenesis Inhibition by Sunitinib on Tumor Distribution of Temozolomide
Zhou, Q., Guo, P., & Gallo, J. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4544 · Cited by 135
Matsumoto, S., Batra, S., Saito, K., Yasui, H., Choudhuri, R., Gadisetti, C., Subramanian, S., Devasahayam, N., Munasinghe, J. P., Mitchell, J. B., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-2025 · Cited by 129
de Lussanet, Q. G., Backes, W. H., Griffioen, A. W., Padhani, A. R., Baeten, C. I. M., van Baardwijk, A. A. W., Lambin, P., Beets, G. L., van Engelshoven, J. M. A., & Beets‐Tan, R. G. H. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.04.052 · Cited by 132
Angiogenesis in cancer: molecular mechanisms, clinical impact
Eichhorn, M., Kleespies, A., Angele, M. K., Jauch, K. ‐., & Bruns, C. J. (2007) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-007-0150-0 · Cited by 156
Molecular Imaging of Antiangiogenic Agents
Rehman, S., & Jayson, G. C. (2005) · The Oncologist · doi:10.1634/theoncologist.10-2-92 · Cited by 138
Decoding tumor angiogenesis: pathways, mechanisms, and future directions in anti-cancer strategies
Liu, X., Zhang, J., Yi, T., Li, H., Tang, X., Liu, D., Wu, D., & Li, Y. (2025) · Biomarker Research · doi:10.1186/s40364-025-00779-x · Cited by 136
Metabolic Plasticity of Melanoma Cells and Their Crosstalk With Tumor Microenvironment
Avagliano, A., Fiume, G., Pelagalli, A., Sanità, G., Ruocco, M. R., Montagnani, S., & Arcucci, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00722 · Cited by 121
Remodeling Components of the Tumor Microenvironment to Enhance Cancer Therapy
Gkretsi, V., Stylianou, A., Papageorgis, P., Polydorou, C., & Stylianopoulos, T. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00214 · Cited by 123
Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma
Zhu, A. X. (2007) · Cancer · doi:10.1002/cncr.23175 · Cited by 128
Schmainda, K. M., Zhang, Z., Prah, M. A., Snyder, B. S., Gilbert, M. R., Sorensen, A. G., Barboriak, D. P., & Boxerman, J. L. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou364 · Cited by 130
Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer
Krämer, I., & Lipp, H. (2007) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2007.00800.x · Cited by 138
Bevacizumab-Induced Normalization of Blood Vessels in Tumors Hampers Antibody Uptake
Arjaans, M., Oude Munnink, T. H., Oosting, S. F., Terwisscha van Scheltinga, A. G. T., Gietema, J. A., Garbacik, E. T., Timmer-Bosscha, H., Lub-de Hooge, M. N., Schröder, C. P., & de Vries, E. G. E. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3518 · Cited by 121
Pérez, D. G., Suman, V. J., Fitch, T. R., AMATRUDA, T. T., Morton, R. F., Jilani, S. Z., Constantinou, C. L., Egner, J. R., Kottschade, L. A., & Markovic, S. N. (2008) · Cancer · doi:10.1002/cncr.23987 · Cited by 125
Anti-Vascular Endothelial Growth Factor Monoclonals in Non-Small Cell Lung Cancer
Sandler, A. B., Johnson, D. H., & Herbst, R. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-040023 · Cited by 133
Salvage therapy with single agent bevacizumab for recurrent glioblastoma
Chamberlain, M. C., & Johnston, S. K. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9957-6 · Cited by 130
Targeting tumor microenvironment: crossing tumor interstitial fluid by multifunctional nanomedicines
Omidi, Y., & Barar, J. (2014) · PubMed · doi:10.5681/bi.2014.021 · Cited by 99
Aberrant vascular architecture in tumors and its importance in drug-based therapies
Munn, L. L. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02686-2 · Cited by 139
Wang, H., Li, M., Rinehart, J. J., & Zhang, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0829-3 · Cited by 131
Functional CT for Quantifying Tumor Perfusion in Antiangiogenic Therapy in a Rat Model
Kan, Z., Phongkitkarun, S., Kobayashi, S., Tang, Y., Ellis, L. M., Lee, T., & Charnsangavej, C. (2005) · Radiology · doi:10.1148/radiol.2363041293 · Cited by 122
Mathematical modeling of cancer progression and response to chemotherapy
Sanga, S., Sinek, J. P., Frieboes, H. B., Ferrari, M., Fruehauf, J. P., & Cristini, V. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.10.1361 · Cited by 128
Huo, M., Wang, H., Zhang, Y., Cai, H., Zhang, P., Li, L., Zhou, J., & Yin, T. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.02.017 · Cited by 123
A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma
Narayana, A., Gruber, D., Kunnakkat, S., Golfinos, J. G., Parker, E. C., Raza, S., Zagzag, D., Eagan, P., & Gruber, M. L. (2011) · Journal of neurosurgery · doi:10.3171/2011.9.jns11656 · Cited by 120
Metadata
- Authors
- Jain, R. K.
- Affiliations
- Harvard University (US)
- Corresponding author
- Jain, Rakesh K.
- Venue
- Nature Medicine
- Published
- 2001-09
- Volume
- 7
- Issue
- 9
- Pages
- 987-989
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W1603230122
- Cited by
- 2,184
- References
- 26
- Citations by year
- 2026: 58 · 2025: 65 · 2024: 61 · 2023: 88 · 2022: 97 · 2021: 91 · 2020: 93 · 2019: 91 · 2018: 69 · 2017: 94 · 2016: 82 · 2015: 106 · 2014: 94 · 2013: 101 · 2012: 124
- FWCI
- 16.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- anti-angiogenic therapy, tumor vasculature normalization, solid tumors, cancer prevention, combination therapy, drug delivery to tumors, tumor vasculature
- MeSH terms
- Blood Vessels, Clinical Trials as Topic, Humans, Neoplasms, Neovascularization, Pathologic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.